Building upon insight from prior studies, the primary objective of this study is to evaluate the therapeutic potential of systemically delivering a Fas-blocking peptide (FBP) to inhibit the Fas–FasL interaction, thereby reducing neuronal cell death in ischemic stroke [48,51]. The gene discussed is FASLG; the disease is ischemic stroke.